Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of AK-01 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors

NCT03092934 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03092934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03092934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of AK-01 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Completed
Start date
May 29, 2017
Completion date
April 20, 2020
Enrollment
13 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, head and neck neoplasms, neoplasm metastasis, neoplasms, small cell lung carcinoma, solid tumor, adult, triple negative breast neoplasms